Edward Morrow Iii Atkinson Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 month, 1 week ago
Edward Morrow Iii Atkinson has an estimated net worth of at least $16.1 million*, as of Oct. 29, 2025. They own 16,852 shares of VRTX stock. They have sold 36,000 shares of VRTX stock since 2021, for an estimated $8.0 million.
Edward Morrow Iii Atkinson $VRTX SEC Form 4 Insider Trading
Edward Morrow Iii Atkinson has filed a total of 9 insider trades in $VRTX since 2021. Their most recent trade was a sale of 2,500 shares, made on Nov 17, 2025. Their largest trade was a sale of 7,288 shares, made on Jun 12, 2024. We estimate that they now own 16,852 shares of $VRTX, worth an estimated $8.1 million.
Insider Trading at $VRTX
There have been a total of 523 insider trades reported at $VRTX since 2021, with 40,000 shares purchased and 1.0 million shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Bastiano Sanna, and Ourania Tatsis. The most recent trade was a sale of 7,000 shares reported by CHARLES F JR WAGNER (EVP, CO & FO), made on Dec 03, 2025.
History of Insider Stock Trades by Edward Morrow Iii Atkinson
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
VRTX
|
Sale | 2,500 | Nov 17, 2025 | Nov. 19, 2025, 5:06 p.m. |
|
VRTX
|
Sale | 2,650 | Feb 27, 2025 | Feb. 28, 2025, 5:36 p.m. |
|
VRTX
|
Sale | 1,767 | Feb 25, 2025 | Feb. 26, 2025, 5:09 p.m. |
|
VRTX
|
Sale | 1,747 | Feb 11, 2025 | Feb. 12, 2025, 5:29 p.m. |
|
VRTX
|
Sale | 7,288 | Jun 12, 2024 | June 13, 2024, 4:09 p.m. |
|
VRTX
|
Sale | 883 | Feb 26, 2024 | Feb. 27, 2024, 5:44 p.m. |
|
VRTX
|
Sale | 1,201 | Feb 21, 2024 | Feb. 23, 2024, 5:16 p.m. |
|
VRTX
|
Sale | 801 | Feb 20, 2024 | Feb. 21, 2024, 5:23 p.m. |
|
VRTX
|
Sale | 913 | Feb 12, 2024 | Feb. 13, 2024, 5:54 p.m. |
ETNB
|
Sale | 6,250 | Jun 01, 2023 | June 5, 2023, 5:03 p.m. |
|
ETNB
|
Sale | 10,000 | Mar 01, 2023 | March 3, 2023, 6:18 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Stuart A Arbuckle, EVP, COO
-
Jeffrey M Leiden, Executive Chairman
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Reshma Kewalramani, CEO & President
-
Joy Liu, SVP, General Counsel
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Carmen Bozic, EVP and CMO
-
David Altshuler, EVP, Chief Scientific Officer
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Jonathan Biller, EVP and Chief Legal Officer
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Amit Sachdev, EVP, Chief Patient Officer
-
Charles F Jr Wagner, EVP, CO & FO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.